S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS
Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.
19m Aug 30, 2021
19m
S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.
16m Aug 26, 2021
16m
S5 Ep35: Krie and Yuan Talk Toxicity Management in Breast Cancer
Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.
19m Aug 23, 2021
19m
S5 Ep34: DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19
Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests and its link with potential racial disparities from the COVID-19 pandemic, and how the community can continue to emphasize the importance of cancer screening while working to close these disparities in cancer care.
18m Aug 19, 2021
18m
S5 Ep33: Chachoua on Leveraging Screening Opportunities in Lung Cancer
Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.
22m Aug 16, 2021
22m
S5 Ep32: Making the Most of Molecular Testing in Breast Cancer
Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
37m Aug 12, 2021
37m
S5 Ep31: FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.
10m Aug 09, 2021
10m
S5 Ep30: Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.
21m Aug 05, 2021
21m
S5 Ep29: Rariy Reviews In-Home Infusion Initiative in Oncology
Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.
18m Aug 02, 2021
18m
S5 Ep28: Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers
Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.
24m Jul 29, 2021
24m
S5 Ep27: Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
Drs Brown and Hussain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
25m Jul 26, 2021
25m
S5 Ep26: FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer
Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.
10m Jul 22, 2021
10m
S5 Ep25: Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.
16m Jul 19, 2021
16m
S5 Ep24: Mayer on the Optimization of SERDs in ER+ Breast Cancer
Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.
19m Jul 15, 2021
19m
S5 Ep23: Wainberg Weighs In on Advances in HER2+ GI Cancers
In our exclusive interview, Wainberg discussed factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more!
10m Jul 12, 2021
10m
S5 Ep22: CTCA Leaders Provide Post-Pandemic Predictions in Oncology
Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.
26m Jul 08, 2021
26m
S5 Ep21: Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers
Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.
16m Jul 05, 2021
16m
S5 Ep20: Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer
Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.
16m Jul 01, 2021
16m
S5 Ep19: Lee-Kim on Fostering a Fulfilling Fellowship in Oncology
Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.
24m Jun 28, 2021
24m
S5 Ep18: Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.
14m Jun 24, 2021
14m
S5 Ep17: Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19
Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.
21m Jun 21, 2021
21m
S5 Ep16: George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline
Dr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.
25m Jun 17, 2021
25m
S5 Ep15: Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer
Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.
15m Jun 14, 2021
15m
S5 Ep14: Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma
Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences and the resulting research evaluating the administration of an investigational toll-like receptor 9 (TLR9) agonist in combination with immunotherapy across a range of liver and pancreatic solid tumors.
12m Jun 10, 2021
12m
S5 Ep13: FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
11m Jun 07, 2021
11m
S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC
Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.
11m Jun 03, 2021
11m
S5 Ep12: Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma
Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.
17m May 31, 2021
17m
S5 Ep11: Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma
Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.
20m May 27, 2021
20m
S5 Ep10: Kaklamani Speaks to a Shifting HER2+ Breast Cancer Paradigm
In our exclusive interview, Kaklamani discussed current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.
13m May 24, 2021
13m
S5 Ep9: UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma
In our exclusive interview, Drs Park, Daniels, Sanghvi, and Kolb, discussed two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.
32m May 20, 2021
32m
S5 Ep8: Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer
In our exclusive interview, Drs Grivas and Wright discussed the goals of the Seattle Cancer Care Alliance Bladder Cancer Multidisciplinary Clinic, data that support the use of a multidisciplinary approach in bladder cancer, and the lingering effects of the COVID-19 pandemic on collaboration across health care specialties.
26m May 17, 2021
26m
S5 Ep7: O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer
In our exclusive interview, O’Dea discussed the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.
16m May 13, 2021
16m
S5 Ep6: Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
In our exclusive interview, Dr. Federico discussed the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.
23m May 10, 2021
23m
S5 Ep5: FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma
Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.
14m May 06, 2021
14m
S5 Ep4: FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma
Dr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.
10m May 03, 2021
10m
S5 Ep3: Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies
In our exclusive interview, Riedel and Van Tine discussed the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.
25m Apr 29, 2021
25m
S5 Ep2: FDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCC
Riad Salem, MD, discusses the unique elements of the radioembolization technology, the data that supported the regulatory approval, and the anticipated future for TheraSphere in HCC.
15m Apr 26, 2021
15m
S5 Ep1: Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies
Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.
20m Apr 22, 2021
20m
S4 Ep50: Saba Spotlights the Nuances of Treating Nasopharygeal Cancer
Dr. Saba shared the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.
18m Apr 19, 2021
18m
S4 Ep49: Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium
Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.
18m Apr 15, 2021
18m
S4 Ep48: FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma
In our exclusive interview, Fowler discussed the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, explained the implications of the regulatory decision on clinical practice, and detailed potential next steps for the PI3Kδ and CK1ε inhibitor.
9m Apr 12, 2021
9m
S4 Ep47: FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer
In our exclusive interview, Weiss discussed the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.
19m Apr 08, 2021
19m
S4 Ep46: Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research
In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.
21m Apr 05, 2021
21m
S4 Ep45: The Marshalls Open a Candid Conversation About Cancer
The Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.
39m Apr 01, 2021
39m
S4 Ep44: Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer
Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.
16m Mar 29, 2021
16m
S4 Ep43: Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer
Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.
19m Mar 25, 2021
19m
S4 Ep42: Borgen Breaks Down the Domino Effect of Expanded Education and Banished Stigmas in Male Breast Cancer
Patrick I. Borgen, MD, discusses male breast cancer in further detail, how he approaches treatment in his male patients with the disease, and what can be done to remove the stigma that men often feel with a breast cancer diagnosis.
16m Mar 22, 2021
16m
S4 Ep41: Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer
In our exclusive interview, Monk and Herzog discussed the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.
21m Mar 18, 2021
21m
S4 Ep40: Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC
In our exclusive interview, Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.
13m Mar 16, 2021
13m
S4 Ep39: Levy Lauds Biomarker-Driven Data in Lung Cancer
Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.
19m Mar 11, 2021
19m